Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer
Status:
Withdrawn
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effectiveness of lapatinib ditosylate (lapatinib) together
with trastuzumab in treating patients with HER2-negative breast cancer that carries HER2 gene
mutations. Lapatinib may kill tumor cells by blocking some of the enzymes needed for cell
division and growth. Trastuzumab, a monoclonal antibody, may block the ability of tumor cells
to grow and spread. Giving lapatinib together with trastuzumab may provide a more effective
treatment for patients with this type of cancer.